Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Table 2 Multivariable analyses of progression-free survival

	Eribulin (n = 91)		Capecitabine (n = 79)
	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p
When the NLR was a definitive prognostic factor
Age (≥60 years vs. <60 years)	0.90 (0.57–1.38)	0.62	0.92 (0.56–1.48)	0.72
HR (positive vs. negative)	0.91 (0.54–1.62)	0.74	1.22 (0.62–2.71)	0.58
HER2 (negative vs. positive)	0.72 (0.30–2.15)	0.52	0.90 (0.27–5.60)	0.89
NLR (<3 vs. ≥3)	0.62 (0.39–1.01)	0.05	0.48 (0.29–0.84)	0.01
When inflammatory markers that predicted PFS were also included
Age (≥60 years vs. <60 years)	0.82 (0.51–1.31)	0.42	0.80 (0.48–1.31)	0.38
HR (positive vs. negative)	0.94 (0.55–1.70)	0.83	1.26 (0.59–2.97)	0.57
HER2 (negative vs. positive)	0.93 (0.37–2.88)	0.89	1.64 (0.44–10.7)	0.49
ALC (≥1,500/µL vs. <1,500/µL)	0.96 (0.57–1.61)	0.89	0.68 (0.38–1.22)	0.19
NLR (<3 vs. ≥3)	0.69 (0.41–1.20)	0.18	0.86 (0.40–1.91)	0.70
LMR (≥5 vs. <5)	1.20 (0.73–1.97)	0.47	0.55 (0.33–0.94)	0.03
PLR (<250 vs. ≥250)	0.40 (0.22–0.75)	0.005	0.79 (0.32–1.99)	0.62

ALC absolute lymphocyte count; CI confidence interval; CRP C-reactive protein; ER oestrogen receptor; HER2 human epidermal growth factor receptor 2; HR hormone receptor; LDH lactate dehydrogenase; LMR lymphocyte-to-monocyte ratio; NLR neutrophil-to-lymphocyte ratio; PFS progression-free survival; PgR progesterone receptor; PLR platelet-to-lymphocyte ratio

ISSN: 1471-2407